What is the common ending for integrase inhibitors?

Integrase inhibitors are a class of antiretroviral drugs used in the treatment of HIV. The common naming convention for this class of medication typically ends with the suffix "-gravir." This suffix is derived from the drug's structure and mechanism of action as they inhibit the integrase enzyme crucial for the integration of viral DNA into the host cell's genome.

For instance, well-known integrase inhibitors such as dolutegravir and bictegravir clearly illustrate this naming pattern. Understanding the suffix helps healthcare professionals and students recognize and categorize drugs within the same pharmacological class, thereby facilitating communication and medication management.

The options that end with different suffixes, such as "-vir" or "-tavir," are more commonly associated with antiviral medications or nucleoside analogs, respectively, and do not specifically relate to integrase inhibitors. The suffix "-line" is often associated with other classes of drugs altogether, which further differentiates it from integrase inhibitors. Thus, recognizing that "-gravir" is the unique identifier for this group helps in identifying and categorizing these medications effectively.